Quantitative mechanistically based dose-response modeling with endocrine-active compounds

Environmental Health Perspectives

Volumn 107, Issue SUPPL. 4, 1999, Pages 631-638

  Andersen, Melvin E ^a,i   Conolly, Rory B ^b   Faustman, Elaine M ^c   Kavlock, Robert J ^d   Portier, Christopher J ^e   Sheehan, Daniel M ^f   Wier, Patrick J ^g   Ziese, Lauren ^h  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^f NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h RCHAS Off Environ Hlth Hazard A   (United States)

ⁱ ICF Kaiser International   (United States)

Author keywords

Endocrine disruptors; Endocrine active compounds; Linkage models mechanistic dose response modeling; Pharmacodynamics; Pharmacokinetics; Risk assessment extrapolations

Indexed keywords

DOSE RESPONSE; ECOLOGY; ENDOCRINE SYSTEM; ENVIRONMENTAL HEALTH; EXPERIMENTAL MODEL; HEALTH; HUMAN; MEDICAL RESEARCH; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICITY TESTING;

EID: 0032857437     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107s4631     Document Type: Review

References (57)

1. U.S. EPA. The Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) and Federal Food, Drug and Cosmetic Act (FFDCA) As Amended by the Food Quality Protection Act (FOPA) of August 3, 1996. 730L97001. Washington, DC:Office of Pesticide Programs, 1997.
2. 104th Congress. Safe Drinking Water Act Amendments of 1996, Public Law 104-182.
3. U.S. EPA. EDSTAC 2nd Final Draft Report. Endocrine Disruptor Screening and Testing Advisory Committee. Washington, DC: U.S. Environmental Protection Agency, 1998.
4. Barton HA, Andersen ME. A model for pharmacokinetics and physiological feedback among hormones of the testicular-pituitary axis in adult male rats: a framework for evaluating effects of endocrine active compounds Toxicol Sci 45:174-187 (1998).
5. U.S. EPA. Proposed Guidelines for Carcinogen Risk Assessment. EPA 600-P-92-003C. Washington, DC:Office of Research and Development, 1996.
6. U.S. EPA. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. EPA/600/8-90/066F. Washington, DC:Office of Research and Development, 1994.
7. McGrath LF, Georgopoulos P, Gallo MA. Application of a biologically-based RFD estimation method to tetrachlorodibenzo-p-dioxin (TCDD) mediated immune suppression and enzyme induction. Risk Anal 16:549-548 (1996).
8. Allen B, Kavlock B, Kimmel C, Faustman E. Dose-response assessment for developmental toxicity. II: Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fundam Appl Toxicol 23:487-495 (1994).
9. Allen BC, Kavlock RJ, Kimmel CA, Faustman EM. Dose-response assessment for developmental toxicity. Ill: Statistical models. Fundam Appl Toxicol 23:498-509 (1994).
10. Kavlock RJ, Allen BC, Faustman EM, Kimmel CA. Dose-response assessments for developmental toxicity. IV: Benchmark doses for fetal weight changes. Fundam Appl Toxicol 26:211-222 (1995).
11. Shuey DL, Lau C, Logsdon TR, Zucker RM, Elstein KH, Narotsky MG, Setzer AW, Kavlock RJ, Rogers JM. Biologically based dose-response modeling in developmental toxicology: biochemical and cellular sequelae of 5-fluorouracil exposure in the developing rat Toxicol Appl Fhamnacol 126:129-144 (1994).
12. Shuey DL, Buckalew AR, Wilke TS, Rogers JM, Abbott BD. Early events following maternal exposure to 5-fluorouracil lead to dysmorphology in cultured embryonic tissues. Teratology 50:379-386 (1994).
13. Leroux BG, Leisenring WM, Moolgavkar SH, Faustman EM. A Biologically-based dose-response model for developmental toxicology. Risk Anal 16:449-458 (1996).
14. Gaido KW, Leonard LS, Lovell S, Gould JC, Babal D, Portier CJ, McDonnell DP. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol Appl Pharmacol 143:205-212 (1997).
15. Limbird LE, Taylor P. Endocrine disrupters signal the need for receptor models and mechanisms to inform policy. Cell 93 :157-163 (1998).
16. Yates FE. Good manners in good modeling: mathematical models and computer simulations of physiological systems. Am J Physiol 234:R159-R160 (1978).
17. Lucier GW, Portier CJ, Gallo MA. Receptor mechanisms and dose-response models for the effects of dioxin. Environ Hearth Perspect 101:36-44 (1993).
18. Andersen ME, Clewell HJ Jr, Frederick CB. Applying simulation modeling to problems in toxicology and risk assessment - a short perspective. Toxicol Appl Pharmacol 133:181-187 (1995).
19. Portier CJ, Kaplan NL. Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. Fundam Appl Toxicol 13:533-544 (1989).
20. Clewell HJ III, Andersen ME. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk.Toxicology 111:315-329 (1996).
21. Parham FM, Kohn MC, Matthews HB, DeRosa C, Portier CJ. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Toxicol Appl Pharmacol 144:340-347(1997).
22. Parharn FM, Portier CJ. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II: Rates of metabolism. Toxicol Appl Pharmacol 151:110-116 (1998).
23. Tong W, Petkins R, Strelitz R, Collantes ER, Keenan S, Welsh WJ, Branham WS, Sheehan DM. Quantitative structure-activity relationships (QSARs) for estrogen binding to the estrogen receptor predictions across species. Environ Health Perspect 105:1116-1124 (1997).
24. Tong W, Perkins R, Xing L, Welsh WJ. Sheehan DM. QSAR Models for binding of estrogenic compounds to estrogen receptor α and β subtypes. Endocrinology 138:4022-4025 (1997).
25. Vanden Heuvel JP, Clark GC, Kohn MC, Tritscher AM, Greenlee WF, Lucier GW, Bell DA. Dioxin-responsive genes: examination of dose-response relationships using quantitative reverse transcriptase-polymerase chain reaction. Cancer Res 54:62-68 (1994).
26. Sheehan D, Branham W. Dissociation of estrogen-induced uterine growth and omithine decarboxylase activity in the postnatal rat. Teratog Carcinog Mutagen 7:411-422 (19871.
27. Andersen ME, Clewell JH, III, Gearhart J, Allen BC. A pharmaco-dynamic model of the rat estrus cycle in relation to endocrine disrupters. J Toxicol Environ Health 51:189-209 (1997).
28. Kohn MC, Sewall CH, Lucier GW, Portier CJ. A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol Appl Pharmacol 165:29-48 (1996).
29. Blumenthal GM, Kohn MC, Portier CJ. A mathematical model of production, distribution, and metabolism of melatonin in mammalian systems. Toxicol Appl Pharmacol 147:83-92 (1997).
30. ILSI-HESI. An Evaluation of EPA's Proposed Guidelines for Carcinogen Risk Assessment Using Chloroform and Dichloroacetate as Case Studies: Report of an Expert Panel. Washington, DC:International Life Sciences Institute, Health and Environmental Sciences Institute, 1997.
31. Conolly RB, Andersen ME. An approach to mechanism-based cancer risk assessment for formaldehyde. Environ Health Perspect 101:169-176 (1993).
32. Andersen ME, Clewell HJ, III, Gargas ML, Smith FA, Reitz RH. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205 (1987).
33. Andersen ME, Clewell HJ III, Barton HA. A Pharmacodynamic model of atrazine effects on estrous cycle characteristics in the Sprague-Dawley rat. In: Triazine Herbicides: Risk Assessment (Ballantine LG, McFarland JE, Hackett DS, eds). Washington, DC:American Chemical Society, 1998:432-447.
34. Kohn MC and Portier CJ. Effects of the mechanism of -receptor-mediated gene expression on the shape of the dose-response curve. Risk Anal 13:565-572 (1993)
35. Andersen ME, Mills JJ, Gargas ML, Kedderis L, Birnbaum LS, Neubert D, Greenlee WF. Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. J Risk Anal 13:25-36 (1993).
36. Andersen ME, Birnbaum LS, Barton HA, Eklund C. Regional Hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetra-chlorodibenzo-p-dioxin evaluated with a multi-compartment geometric model of hepatic zonation. Toxicol Appl Pharmacol 144:145-155 (1997).
37. U.S. EPA. Assessment of Thyroid Follicular Cell Tumors. EPA/630/R-97-002. Washington, DC:U.S. Environmental Protection Agency, 1998.
38. Cook JC. Foster PMD, Hardisty JF, Klinefelter GR, Sharpe RM. A review of Leydig cell hyperplasia in rodents and their relevance to man. Crit Rev Toxicol 29:169-261 (1999).
39. Faustman EM, Lawandowski TA, Ponce RA, Bartell SM. Biologically based dose-response models for developmental toxicants: lessons from methylmercury. Inhal Toxicol 11:101-114 (1999).
40. Kavlock RJ, Setzer RW. The road to embryologically based dose-response models. Environ Health Perspect 104:107-121 (19961.
41. Daston GP, Gooch JW, Breslin WJ, Shuey DL, Nikiforov Al, Fico TA, Gorsuch JW. Environmental estrogens and reproductive health: a discussion of the human and environmental data. Reprod Toxicol 11:485-481 (1997).
42. vom Saal FS, Timms GG, Montano MM, Palanza P, Thayer KA, Nagel SC, Dhar MD, Ganjam VK, Parmigiani S, Welshons WV. Prostate enlargement in mice due to fetal exposure to low doses of estradiol and diethylstilbestrol and opposite effects at high boses. Proc Natl Acad Sci USA 94:2055-2061 (1997).
43. Crews D, Bergeron JM, Bull JJ, Flores D, Tousignant A, Skipper JK, Wibbels T. Temperature-dependent sex determination in reptiles: proximate mechanisms, ultimate outcomes and practical applications. Dev Genet 15:297-312 (1994).
44. Crews D, Cantu AR, Bergeron JM. Temperature and non-aromatizable androgens: a common pathway in male sex determination in a turtle with temperature-dependent sex determination? J Endocrinol 149:457-463 (1996).
45. McLachlan JA, Newbold RR, Shah HC, Hogan MD, Dixon RL. Reduced fertility in female mice exposed transplacentally to diethylstilbestrol (DES). Fertil Steril 38:364-371 (1982).
46. Gray LE, Wolf C, Mann P, Ostby JS. In utero exposure to low doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin alters reproductive development of female Long Evans hooded rat offspring. Toxicol Appl Pharmacol 146:237-244 (1997).
47. Andersen ME, Barton HA. Biological regulation of receptor-hormone complex concentrations in relation to dose response assessments for endocrine active compounds. Toxicol Sci (in press). 48:38-50 (1999).
48. Shapiro DJ, Barton MC, McKearin DM, Chang T-C, Lew D, Blume J, Nielsen DA, Gould L. Estrogen regulation of gene transcription and mRNA stability. Recent Prog Norm Res 45:29-64 (1989).
49. Tata JR, Baker BS. Machuca I, Rabelo EML, Yamauchi K. Autoinduction of nuclear receptor genes and its significance. J Steroid Biochem Mol Biol 46:105-119 (1993).
50. Ferrell JE Jr, Machleder EM. The biochemical basis of an all-or-none cell fate switch in xenopus oocytes. Science 2B0: 895-353 (1998).
51. Kohn MC, Lucier GW, Clark GC, Sewall C, Tritscher A, Portier CJ. A mechanistic model of the effects of dioxin on gene expression in the rat liver. Toxicol Appl Pharmacol 120: 13B-154 (1993).
52. Conolly RB, Andersen ME. Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and CYP 1A1AZ as a dosimeter. Toxicol Appl Pharmacol 146:281-293 (1997).
53. Frederick CB, Bush ML, Lomax LG, Black KA, Finch L, Kimbell JS, Morgan KT, Subramaniam RP. Morris JB, Ultman JS. Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper air-ways. Toxicol Appl Pharmacol 152:211-231 (1998).
54. Tsai TL. Katzenellenbogen BS. Antagonism of development and growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by the antiestrogen U 23,469 and effects on estrogen and progesterone receptors. Cancer Res 37: 1537-1543 (1977).
55. Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938-967 (1996).
56. Constan AA, Yang RSH, Baker DC, Benjamin SA. A unique pattern of hepatocellular proliferation in F344 rats following long-term, low-level exposure to a chemical mixture of groundwater contaminants. Carcinogenesis 16:303-310 (1995).
57. Reiter LW, DeRosa C, Kavlock RJ, Lucier G, Mac MJ, Melillo J, Melnick RL, Sinks T, Walton BT. The U.S. federal framework for research on endocrine disruptors and an analysis of research programs supported during fiscal year 1996. Environ Health Perspect 106:105-113 (1998).